Peripheral Vascular Stents Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Peripheral vascular stents are small, expandable mesh tubes used in angioplasty procedures to restore adequate blood flow in peripheral arteries affected by atherosclerosis, stenosis, or occlusion. The global stents market, encompassing coronary, peripheral, and other vascular applications, was valued at approximately $10.1 billion in 2025 and is projected to reach $10.8 billion in 2026, with long-term forecasts extending toward $22-25 billion by the early 2030s depending on scope. Coronary artery stents historically dominated the vascular stent landscape, representing roughly two-thirds of the total vascular stent market as of the mid-2010s, leaving peripheral vascular stents as a substantial and rapidly growing secondary segment.

• •Global stents market valued at ~$10.1B in 2025, rising to ~$10.8B in 2026 with a 7.4% CAGR trajectory
• •Coronary stents historically accounted for roughly two-thirds of the vascular stent market, leaving peripheral as the next-largest segment
• •North America vascular stents market alone reached ~$4.1B in 2025, indicating the broader global context for all stent types

The dominant driver of market expansion is the rising global burden of peripheral artery disease (PAD), which affects hundreds of millions of adults and is strongly correlated with diabetes, obesity, smoking rates, and population aging. Technological evolution, including the shift from bare-metal to drug-eluting and bioabsorbable stent platforms, as well as improvements in radial and catheter-based delivery systems, has improved clinical outcomes and broadened the treatable patient population. Additionally, growing adoption of minimally invasive endovascular procedures over open surgical bypass, driven by shorter recovery times and lower complication rates, continues to expand the addressable procedure volume.

• •Rising global prevalence of peripheral artery disease driven by aging demographics and lifestyle-related risk factors (diabetes, obesity, smoking)
• •Technology shifts toward drug-eluting stents and bioresorbable platforms improving clinical outcomes and procedural adoption
• •Growing preference for minimally invasive endovascular procedures over open surgical reconstruction expanding treatable patient volumes

The market is segmented by product type, bare-metal stents, drug-eluting stents, and bioabsorbable stents, with drug-eluting platforms increasingly capturing share due to superior patency and lower restenosis rates. Anatomically, the peripheral segment spans iliac, femoral-popliteal, and tibial artery interventions, each with distinct clinical requirements and device designs. Regionally, North America leads in absolute value, supported by advanced healthcare infrastructure, favorable reimbursement frameworks, and high disease prevalence. Europe and Japan follow as mature markets, while Asia-Pacific, particularly China and India, is emerging as the fastest-growing region driven by rising healthcare spending, expanding catheterization laboratory capacity, and increasing disease awareness.

• •Product segmentation: bare-metal, drug-eluting, and bioabsorbable stents, with drug-eluting platforms gaining share
• •Anatomical sub-segments include iliac, femoral-popliteal, and tibial arteries, each requiring distinct stent designs
• •North America is the largest regional market; Asia-Pacific is projected as the fastest-growing due to healthcare infrastructure expansion and rising disease prevalence

Who are the notable companies in the industry?

The peripheral vascular stents market is moderately consolidated, with large diversified medical technology corporations operating alongside more focused specialty cardiovascular device producers. **Abbott** anchors a broad peripheral intervention portfolio spanning self-expanding systems such as Supera™, with interwoven wires designed to mimic dynamic vessel movement in the SFA and proximal popliteal, and Absolute Pro™, which uses tri-axial technology for precise placement, as well as balloon-expanding platforms including the Omnilink Elite™, built on cobalt-chromium multi-link technology, and the Herculink Elite™ for renal arteries. **COOK Medical** and **BD** are recognized among the leading brands offering peripheral stent lines, reflecting the role of diversified device manufacturers with established peripheral intervention footprints. **Alvimedica** and **Balton** contribute as additional specialized competitors, while **InSitu Technologies** operates as a focused peripheral stent developer. **Bard Medical** appears as a named competitor in peripheral stent listings, and **Cordis** rounds out the field as an established peripheral vascular intervention brand. Across the competitive set, manufacturers differentiate through delivery system visibility, mesh geometry, and procedural data, rather than uniform platform technology.

• •Market structure is moderately consolidated with a mix of large diversified med-tech firms and focused specialty producers
• •Technology routes span traditional metal alloy platforms (nitinol, cobalt-chromium) and emerging bioabsorbable/drug-eluting coatings
• •Manufacturing and R&D capacity is concentrated in North America, Western Europe, and East Asia, with contract manufacturing playing a meaningful role

What are the recent trends and outlook?

Key emerging trends include the development of fully bioresorbable vascular scaffolds, next-generation drug-eluting coatings with improved biocompatibility, and the integration of imaging-guided precision techniques such as intravascular ultrasound and optical coherence tomography to optimize stent placement. Value-based care models and healthcare cost containment pressures are incentivizing devices that demonstrate durable clinical outcomes and cost-effectiveness over the product lifecycle. Through 2030-2035, the market is expected to sustain a 7-9% annual growth trajectory, with long-term projections for the overall stents market reaching approximately $22-26 billion, supported by continued demographic tailwinds and incremental procedural volume growth across both developed and emerging economies.

• •Emerging technologies include bioresorbable vascular scaffolds and next-generation drug-eluting coatings with enhanced biocompatibility
• •Value-based care and reimbursement scrutiny are driving emphasis on devices with proven long-term clinical and cost-effectiveness
• •Long-term market forecasts project overall stents market reaching $22-26B by the early 2030s, with peripheral stents contributing a growing share of that total